tetano
Editor, Senior Moderator
Intern Med
. 2022 Sep 6.
doi: 10.2169/internalmedicine.0293-22. Online ahead of print.
Medium-vessel Vasculitis Presenting with Myalgia Following COVID-19 Moderna Vaccination: A Case Report
Shin-Ichiro Ohmura[SUP] 1 [/SUP], Yusuke Ohkubo[SUP] 1 [/SUP], Ryuhei Ishihara[SUP] 1 [/SUP], Yoshiro Otsuki[SUP] 2 [/SUP], Toshiaki Miyamoto[SUP] 1 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) vaccines have been delivered worldwide to prevent the spread of the disease, and almost all Japanese have received the mRNA vaccines "BNT162b2" (Pfizer-Biotech) or "mRNA-1273" (Moderna). These vaccines have shown efficacy and safety with only minor adverse drug reactions. However, some patients develop severe adverse drug reactions, including autoimmune reactions. In addition, systemic vasculitis, mainly small-vessel vasculitis, following COVID-19 vaccination, has been reported. However, only a few investigators have reported medium-vessel vasculitis following vaccination. We herein report a case of medium-vessel vasculitis presenting with myalgia as the initial clinical manifestation following COVID-19 Moderna vaccination.
Keywords: COVID-19; autoimmune phenomena; mRNA vaccine; medium-vessel vasculitis; myalgia.
. 2022 Sep 6.
doi: 10.2169/internalmedicine.0293-22. Online ahead of print.
Medium-vessel Vasculitis Presenting with Myalgia Following COVID-19 Moderna Vaccination: A Case Report
Shin-Ichiro Ohmura[SUP] 1 [/SUP], Yusuke Ohkubo[SUP] 1 [/SUP], Ryuhei Ishihara[SUP] 1 [/SUP], Yoshiro Otsuki[SUP] 2 [/SUP], Toshiaki Miyamoto[SUP] 1 [/SUP]
Affiliations
- PMID: 36070946
- DOI: 10.2169/internalmedicine.0293-22
Abstract
Coronavirus disease 2019 (COVID-19) vaccines have been delivered worldwide to prevent the spread of the disease, and almost all Japanese have received the mRNA vaccines "BNT162b2" (Pfizer-Biotech) or "mRNA-1273" (Moderna). These vaccines have shown efficacy and safety with only minor adverse drug reactions. However, some patients develop severe adverse drug reactions, including autoimmune reactions. In addition, systemic vasculitis, mainly small-vessel vasculitis, following COVID-19 vaccination, has been reported. However, only a few investigators have reported medium-vessel vasculitis following vaccination. We herein report a case of medium-vessel vasculitis presenting with myalgia as the initial clinical manifestation following COVID-19 Moderna vaccination.
Keywords: COVID-19; autoimmune phenomena; mRNA vaccine; medium-vessel vasculitis; myalgia.